Indegene Ltd

AI
Indegene Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Indegene Ltd

₹ 568 0.19%
21 Aug - close price
indegene.com BSE: 544172 NSE: INDGN
About

Incorporated in 1998, Indegene Ltd provides
solutions consisting of analytics, technology
and commercial, medical, regulatory and
safety services to life science and health
care organizations[1]

Key Points

Business Overview [1]
The company is a strategic operating partner to the global life sciences industry, supporting commercial, medical, R&D, and safety operations across the product lifecycle. It combines deep life sciences expertise with AI-enabled platforms, data analytics, and governed operating models, servicing the world’s top 20 biopharma companies. Its capabilities span five key areas: Discovery & Evidence, Regulatory & Compliance, Commercial Launch, Content & Engagement, and Patient & Outcomes.

Website BSE NSE
  • Market Cap ₹ 13,679 Cr.
  • Current Price ₹ 568
  • High / Low ₹ 597 / 414
  • Stock P/E 60.3
  • Book Value ₹ 86.4
  • Dividend Yield 0.40 %
  • ROCE 14.3 %
  • ROE 10.7 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 17.3%
  • Debtor days have improved from 119 to 86.2 days.
  • Company's working capital requirements have reduced from 91.9 days to 50.8 days

Cons

  • Company has a low return on equity of 12.0% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Services Healthcare Research, Analytics & Technology

Part of Nifty 500 BSE 250 SmallCap Index Nifty500 Equal Weight Nifty500 LargeMidSmall Equal-Cap Weighted BSE 1000

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
252 260 260 272 259 282 287 267 256 307 290 368 341
215 217 223 226 219 235 235 227 219 236 252 265 280
Operating Profit 38 43 37 46 40 46 52 40 37 71 38 103 60
OPM % 15% 17% 14% 17% 15% 16% 18% 15% 14% 23% 13% 28% 18%
12 6 12 23 14 22 22 35 32 18 23 6 34
Interest 2 2 2 2 2 2 2 2 2 2 2 3 3
Depreciation 9 8 6 8 7 6 6 7 7 9 10 11 11
Profit before tax 39 39 41 60 45 61 66 66 60 78 49 95 80
Tax % 24% 26% 27% 19% 28% 27% 25% 18% 25% 23% 29% 24% 25%
30 29 30 49 33 45 50 54 45 60 35 72 60
EPS in Rs 1.33 1.32 1.33 2.20 1.36 1.87 2.08 2.26 1.88 2.49 1.45 2.99 2.49
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
282 334 511 837 1,006 1,046 1,094 1,221 1,306
230 249 361 668 828 878 913 972 1,034
Operating Profit 53 86 150 169 178 168 180 248 272
OPM % 19% 26% 29% 20% 18% 16% 17% 20% 21%
12 -24 30 28 37 50 90 78 80
Interest 1 3 4 3 6 7 6 9 10
Depreciation 4 13 18 24 32 31 26 36 40
Profit before tax 59 46 159 170 177 181 238 281 302
Tax % 14% 30% 17% 22% 26% 24% 24% 25%
51 32 132 133 130 138 181 212 227
EPS in Rs 324.22 202.30 843.58 755.26 5.87 6.20 7.55 8.80 9.42
Dividend Payout % 0% 0% 0% 0% 0% 0% 26% 26%
Compounded Sales Growth
10 Years: %
5 Years: 19%
3 Years: 7%
TTM: 20%
Compounded Profit Growth
10 Years: %
5 Years: 10%
3 Years: 18%
TTM: 17%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: -1%
Return on Equity
10 Years: %
5 Years: 14%
3 Years: 12%
Last Year: 11%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 0.31 0.30 0.30 0.40 44 44 48 48
Reserves 158 -3 254 650 751 909 1,840 2,032
106 362 23 44 51 38 27 70
57 72 96 156 191 228 234 332
Total Liabilities 322 431 373 850 1,038 1,220 2,150 2,482
8 31 41 72 78 56 53 113
CWIP 0 0 0 0 0 0 4 12
Investments 134 251 83 203 400 624 975 1,318
180 148 249 575 559 540 1,119 1,039
Total Assets 322 431 373 850 1,038 1,220 2,150 2,482

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
62 90 53 38 82 176 129 346
-70 -51 -34 -267 -51 -189 -824 -270
15 -18 -37 245 -17 -16 717 -63
Net Cash Flow 8 20 -18 16 14 -29 22 13
Free Cash Flow 60 84 35 17 66 166 112 302
CFO/OP 145% 122% 52% 44% 70% 134% 111% 159%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 65 65 125 152 145 132 140 86
Inventory Days
Days Payable
Cash Conversion Cycle 65 65 125 152 145 132 140 86
Working Capital Days 16 -12 76 103 113 104 121 51
ROCE % 28% 49% 36% 24% 18% 17% 14%

Insights

In beta
Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
$1M+ Clients
Count

Log in to view insights

Please log in to see hidden values.

Login
Active Client Relationships
Count
Total Employees
Count
$25M+ Strategic Clients
Count
Top 20 Customer Revenue
INR Mn
Revenue per Employee
USD
Net Revenue Retention
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

11 Recently
Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
3.79% 4.82% 5.03% 5.24% 10.04% 11.30% 11.48% 10.27% 9.92%
3.84% 3.17% 3.99% 4.96% 7.20% 6.95% 8.06% 8.29% 8.74%
92.38% 92.01% 91.01% 89.80% 82.75% 81.74% 80.44% 81.43% 81.34%
No. of Shareholders 2,03,5991,51,4401,53,7891,44,7081,51,9971,51,8091,47,1821,42,1191,38,533

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Concalls